



(51) International Patent Classification:

A61K 31/4439 (2006.01) A61K 31/541 (2006.01)  
A61K 31/5025 (2006.01) A61K 45/06 (2006.01)  
A61K 31/506 (2006.01) A61P 35/00 (2006.01)  
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2024/045997

(22) International Filing Date:

10 September 2024 (10.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/581,969 11 September 2023 (11.09.2023) US  
63/572,066 29 March 2024 (29.03.2024) US

(71) Applicant: **KUMQUAT BIOSCIENCES INC.** [US/US];  
10770 Wateridge Circle, Suite 120, San Diego, California  
92121 (US).

(72) Inventors: **LIU, Yi**; 10770 Wateridge Circle, Suite 120,  
San Diego, California 92121 (US). **UYEI, Anne**; 10770  
Wateridge Circle, Suite 120, San Diego, California 92121  
(US). **JANES, Matthew R.**; 10770 Wateridge Circle, Suite  
120, San Diego, California 92121 (US). **CHEN, Jeffrey**;


10770 Wateridge Circle, Suite 120, San Diego, California  
92121 (US).

(74) Agent: **MALECHA, James**; Wilson Sonsini Goodrich &  
Rosati, 650 Page Mill Road, Palo Alto, California 94304  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: **SOS1 INHIBITORS FOR USE IN THE TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE BLOOD CANCERS**



(57) Abstract: The present disclosure provides SOS-1 inhibitors, such as bicyclic compounds or macrocyclic compounds, alone or in combination with TKI - resitant to BCR-ABL tyrosine kinase, such as dasatinib or imatinib, for use in the treatment of philadelphia chromosome positive (Ph<sup>+</sup>) blood cancer, such as CML (chronic myelogenous leukemia, also named chronic myeloid leukemia), Ph+ALL (acute lymphoblastic leukemia) and Ph+AML (acute lymphoblastic lymphoma).

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*